Citations

Clear

14 citation(s) found for "Liu, Ping".

Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure—Minnesota, 2021
Holzbauer, Stacy , Prabhu, Rajesh M. , Asch-Kendrick, Rebecca J, Ireland, Malia , Klumb, Carrie , Firestone, Melanie J. , Liu, Gong‐Ping , Harry, Katie, Ritter, Jana M. , Orciari, Lillian A., Wilkins, Kimberly , Yager, Pamela A., Gigante, Crystal M. , Zhao, Hui , Niezgoda, Michael, Li, Yu , Levis, Robin, Scott, Dorothy E. , Satheshkumar, Panayampalli S. , Petersen, Brett W. , Rao, Agam K. , Bell, William R. , Bjerk, Sonja, Forrest, Sara, Gao, Wangcai, Dasheiff, Richard M., Russell, Kari, Pappas, Melissa , Kiefer, Jessica , Bickler, Wesley, Wiseman, Anthony, Jurantee, Joel, Reichard, R. Ross , Smith, Kirk , Lynfield, Ruth , Scheftel, Joni, Wallace, Ryan M. , Bonwitt, Jesse , Schrodt, Caroline A. , Levine, Min Z. , Ellison, James A.

Mayo Clinic

Clinical Infectious Diseases | March 30, 2023 | Volume: 77 | Issue: 8 | Pages: 1201-1208

10.1093/cid/ciad098 | PMID 36988328 Get It

Abstract Background No human rabies post-exposure prophylaxis (PEP) failure has been documented in the United States using modern cell culture–based vaccines. In January 2021, an 84-year-old male died from rabies 6 months after being bitten by a rabid bat despite receiving timely rabies PEP. We investigated the cause of breakthrough infection. Methods We reviewed medical records, laboratory results, and autopsy findings and performed whole-genome sequencing (WGS) to compare patient and bat virus sequences. Storage, administration, and integrity of PEP biologics administered to the patient were assessed; samples from leftover rabies immunoglobulin were evaluated for potency. We conducted risk assessments for persons potentially exposed to the bat and for close patient contacts. Results Rabies virus antibodies present in serum and cerebrospinal fluid were nonneutralizing. Antemortem blood testing revealed that the patient had unrecognized monoclonal gammopathy of unknown significance. Autopsy findings showed rabies meningoencephalitis and metastatic prostatic adenocarcinoma. Rabies virus sequences from the patient and the offending bat were identical by WGS. No deviations were identified in potency, quality control, administration, or storage of administered PEP. Of 332 persons assessed for potential rabies exposure to the case patient, 3 (0.9%) warranted PEP. Conclusions This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture–based vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is any suspicion for immunocompromise.
The Jarvik 2000 Left Ventricular Assist Device: Results of the United States Bridge to Transplant Trial
Selzman, Craig H. , Feller, Erika , Walker, Jordan C., Sheridan, Brett C. , Daly, Richard C. , Anyanwu, Ani C., Madigan, Dave, Liu, Ping‐Yu , Frazier, O.H., Jorde, Ulrich P. , Griffith, Bartley P. , Silvestry, Scott

Mayo Clinic

ASAIO Journal | April 14, 2022 | Volume: 69 | Issue: 2 | Pages: 174-182

10.1097/mat.0000000000001750 | PMID 35421002 Get It

The Jarvik 2000 bridge to transplant investigational device exemption study was a multicentered, prospective study of 150 UNOS status I patients implanted with the Jarvik 2000 between 2005 and 2012. During the study period, there were numerous modifications of the system that included converting from pin to cone bearings. Results were analyzed for three cohorts: total (n = 150), pin (n = 128), and cone (n = 22). Baseline demographics included age (52 ± 13), gender (79% male), size (BSA 1.98), and etiology (37% idiopathic dilated cardiomyopathy; 43% Ischemic). Seventy percent of patients were either INTERMACS 1 or 2. The primary endpoint—defined as successful transplantation or listing at 180 days (prespecified at 65%; 95% lower CI: 57%)—was successfully achieved for the total cohort (67.3%; 95% CI: 59.5%–74.3%; p = 0.006). In subgroup analysis of the more contemporary, cone-bearing group, the primary endpoint was met in 91% (95% CI: 72%–97.5%; p = 0.001). Compared with pin patients, cone-bearing patients had less hemolysis as well as decreased end-organ dysfunction. Functional and quality of life scores improved after implantation independent type of bearing. In conclusion, despite a particularly sick patient population, the Jarvik 2000 was shown to be effective in supporting the advanced HF patient.
Six-month outcomes and effect of pulmonary rehabilitation among patients hospitalized with COVID-19: a retrospective cohort study
Dun, Yaoshan , Ripley-Gonzalez, Jeffrey W. , Liu, Ping , Zhou, Nanjiang , Gong, Xun , You, Baiyang, Du, Yang , Liu, Jiyang , Li, Bo , Liu, Suixin , Liu, Suixin , Liu, Suixin , Dun, Yaoshan , Liu, Chao

Mayo Clinic

Annals of Medicine | November 12, 2021 | Volume: 53 | Issue: 1 | Pages: 2099-2109

10.1080/07853890.2021.2001043 | PMID 34766857 Get It

Abstract 873: Molecular mechanisms of non-small cell lung cancer growth and drug resistance
Astone, Matteo , Liu, Ping , Coyle, Abbygail M. , Dankert, Erin N. , Hoffman, Dane K. , Hall, Stephanie R., Kuang, Rui , Roden, Anja C. , Alam, Sk. Kayum , Wang, Li , Zhang, Wei , Mansfield, Aaron S. , Hoeppner, Luke H.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 873-873

10.1158/1538-7445.am2019-873 Get It

Abstract Lung cancer is the deadliest and most frequently diagnosed type of tumor worldwide, with 1.6 million deaths reported annually. Non-small cell lung cancer (NSCLC) represents 85% of all lung cancer cases and carries a poor 5-year survival rate below 15%. Prognoses remain dismal due to the large number of patients diagnosed with advanced stage disease and the development of resistance to current therapies. A better understanding of acquired drug resistance will help to circumvent the progression of lung cancer and make significant strides in improving NSCLC patient treatment. Our recent work demonstrates that dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its amino-terminally truncated splice variant (t-DARPP) promote lung tumor growth in orthotopic mouse models. IHC staining of 62 human lung adenocarcinoma tissues showed that t-DARPP expression is elevated with increasing tumor (T) staging score, which represents the size of the primary tumor and whether it has grown into nearby areas, as a metric of tumor progression and growth. Correspondingly, a computational biology analysis of 513 lung adenocarcinoma patients revealed upregulation of t-DARPP isoform expression correlates with advanced T stage and is associated with poor overall survival. We identified a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through activation of non-canonical NF-κB2 signaling. It has been shown that DARPP-32 overexpression inhibits gefitinib-induced apoptosis in gastric cancer and t-DARPP contributes to the trastuzumab resistance phenotype in breast cancer. Our recent findings suggest DARPP-32 and t-DARPP overexpression in NSCLC promotes resistance to specific molecular targeted inhibitors by enabling tumor cells to evade apoptosis via Akt- and Erk-dependent cell survival mechanisms. Current ongoing studies are focused on manipulating expression of DARPP-32 isoforms in lung tumor cells to prevent resistance to targeted therapies in NSCLC patients. Citation Format: SK Kayum Alam, Matteo Astone, Ping Liu, Li Wang, Abbygail M. Coyle, Erin N. Dankert, Dane K. Hoffman, Stephanie R. Hall, Wei Zhang, Rui Kuang, Anja C. Roden, Aaron S. Mansfield, Luke H. Hoeppner. Molecular mechanisms of non-small cell lung cancer growth and drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 873.
Abstract 5161: DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration and Akt/Erk-mediated cell survival
Alam, Sk. Kayum , Astone, Matteo , Hall, Stephanie R., Coyle, Abbygail M. , Dankert, Erin N. , Hoffman, Dane K. , Zhang, Wei , Kuang, Rui , Roden, Anja C. , Liu, Ping , Mansfield, Aaron S. , Hoeppner, Luke H.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5161-5161

10.1158/1538-7445.am2018-5161 Get It

Abstract Lung cancer is the leading cause of cancer-related death worldwide. In this study, we demonstrate that elevated expression of dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000 (DARPP-32) and its truncated splice variant t-DARPP promotes lung tumor growth, while abrogation of DARPP-32 expression in human non-small cell lung cancer (NSCLC) cells reduces tumor growth in orthotopic mouse models. We observe a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NF-κB2) signaling. Bioinformatics analysis of 513 lung adenocarcinoma patients reveals elevated t-DARPP isoform expression is associated with poor overall survival. Histopathological investigation of 62 human lung adenocarcinoma tissues also showed that t-DARPP expression is elevated with increasing tumor (T) stage. Our data suggest that DARPP-32 is a negative prognostic marker associated with increasing stages of NSCLC and may represent a novel therapeutic target. Citation Format: Sk. Kayum Alam, Matteo Astone, Ping Liu, Stephanie R. Hall, Abbygail M. Coyle, Erin N. Dankert, Dane K. Hoffman, Wei Zhang, Rui Kuang, Anja C. Roden, Aaron S. Mansfield, Luke H. Hoeppner. DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration and Akt/Erk-mediated cell survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5161.
Surveillance for and Discovery of Borrelia Species in US Patients Suspected of Tickborne Illness
Kingry, Luke C. , Anacker, Melissa , Pritt, Bobbi S. , Bjork, Jenna , Respicio-Kingry, Laurel, Liu, Gong‐Ping , Sheldon, Sarah W., Boxrud, David, Strain, Anna K., Oatman, Stephanie, Berry, Jon, Sloan, Lynne M., Mead, Paul S. , Neitzel, David F., Kugeler, Kiersten J. , Petersen, Jeannine M., Pritt, Bobbi, Sloan, Lynne, Kingry, Luke , Pritt, Bobbi S , Berry, Jonathan

Mayo Clinic

Clinical Infectious Diseases | December 17, 2017 | Volume: 66 | Issue: 12 | Pages: 1864-1871

10.1093/cid/cix1107 | PMID 29272385 Get It

CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion
Fan, Long, Zhu, Qingyi , Zhu, Cuicui , Lu, Shan , Liu, Ping , Liu, Li , Huang, Haojie

Mayo Clinic

Oncotarget | June 7, 2017 | Volume: 8 | Issue: 32 | Pages: 53244-53261

10.18632/oncotarget.18387 | PMID 28881808 Get It

Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States
Pritt, Bobbi S. , Respicio-Kingry, Laurel, Sloan, Lynne M., Schriefer, Martin E., Replogle, Adam J., Bjork, Jenna , Liu, Gong‐Ping , Kingry, Luke C. , Mead, Paul S. , Neitzel, David F., Schiffman, Elizabeth , Johnson, Diep K. Hoang, Davis, Jeffrey P., Paskewitz, Susan M. , Boxrud, David, Deedon, Alecia, Lee, Xia , Miller, Tracy K., Feist, Michelle, Steward, Christopher R., Theel, Elitza S. , Patel, Robin , Irish, Cole L., Petersen, Jeannine M., Patel, Robin , Kingry, Luke , Pritt, Bobbi S

Mayo Clinic

International Journal of Systematic and Evolutionary Microbiology | August 24, 2016 | Volume: 66 | Issue: 11 | Pages: 4878-4880

10.1099/ijsem.0.001445 | PMID 27558626 Get It

CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy
Ding, Liya , Pan, Yunqian , Zhong, Jian , Regan, Kevin M., Wang, Liguo , Yu, Chunrong, Rizzardi, Anthony E., Zhang, Jun , Schmechel, Stephen C. , Cheville, John C. , Deursen, Jan van, Tindall, Donald J., Cheng, Liang , Chen, Daiwen , Liu, Ping , Cheng, Liang , Huang, Haojie , Wang, Liguo , Cheng, Liang

Mayo Clinic

Cancer Research | February 3, 2014 | Volume: 74 | Issue: 7 | Pages: 2050-2061

10.1158/0008-5472.can-13-1659 | PMID 24491799 Get It

Abstract Despite the high incidence and mortality of prostate cancer, the etiology of this disease is not fully understood. In this study, we develop functional evidence for CBP and PTEN interaction in prostate cancer based on findings of their correlate expression in the human disease. Cbppc−/−;Ptenpc+/− mice exhibited higher cell proliferation in the prostate and an early onset of high-grade prostatic intraepithelial neoplasia. Levels of EZH2 methyltransferase were increased along with its Thr350 phosphorylation in both mouse Cbp−/−; Pten+/− and human prostate cancer cells. CBP loss and PTEN deficiency cooperated to trigger a switch from K27-acetylated histone H3 to K27-trimethylated bulk histones in a manner associated with decreased expression of the growth inhibitory EZH2 target genes DAB2IP, p27KIP1, and p21CIP1. Conversely, treatment with the histone deacetylase inhibitor panobinostat reversed this switch, in a manner associated with tumor suppression in Cbppc−/−;Ptenpc+/− mice. Our findings show how CBP and PTEN interact to mediate tumor suppression in the prostate, establishing a central role for histone modification in the etiology of prostate cancer and providing a rationale for clinical evaluation of epigenetic-targeted therapy in patients with prostate cancer. Cancer Res; 74(7); 2050–61. ©2014 AACR.